EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Olverembatinib: A New Treatment for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Xavier Thomas iD

Cancers · 18.06.2026 · 18 (12) · 1990

DOI: 10.3390/cancers18121990 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.06.2026. Verfasst von Xavier Thomas. Beteiligte Einrichtung: Hospices Civils de Lyon, Department of Clinical Hematology, Centre Hospitalier Universitaire, F-69003 Lyon, France. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The prognosis of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has improved with the addition of tyrosine kinase inhibitors (TKIs) to conventional chemotherapy. However, there are limited therapeutic options for patients resistant or intolerant to current TKIs.

Methods

A comprehensive search was made on PubMed.ncbi.nlm.nih.gov for published studies and ClinicalTrials.gov for registered trials, regarding the first results of and promising strategies with olverembatinib, a novel third-generation TKI, for the treatment of Ph+ ALL.

Results

First trials involving olverembatinib showed significant anti-leukemic clinical activity both in newly diagnosed and relapsed/refractory patients with Ph+ ALL, especially those harboring the T315I mutation. Furthermore, olverembatinib demonstrated a favorable tolerability compared with the other TKIs.

Conclusions

This augurs a new era in the standard of care for many patients with unmet clinical needs. However, further studies are warranted to assess olverembatinib’s real value and its cost-effectiveness.

Schlagwörter

Stichwörter der Autor:innen

Philadelphia chromosomeT315I mutationacute lymphoblastic leukemiaolverembatinibprognosistreatmenttyrosine kinase inhibitors

Autor:innen und Institutionen

  • Hospices Civils de Lyon, Department of Clinical Hematology, Centre Hospitalier Universitaire, F-69003 Lyon, France.

ORCID-Profile: Xavier Thomas

Zitieren

APA

Thomas, X. (2026). Olverembatinib: A New Treatment for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Cancers, 18(12), 1990. https://doi.org/10.3390/cancers18121990

Vancouver

Thomas X. Olverembatinib: A New Treatment for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Cancers. 2026;18(12):1990. doi:10.3390/cancers18121990

BibTeX
@article{Thomas2026,
  author = {Thomas, Xavier},
  title = {Olverembatinib: A New Treatment for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {12},
  pages = {1990},
  doi = {10.3390/cancers18121990}
}
Kostenlos starten →